Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Myelosuppression is a potential dose-limiting factor in radioligand therapy (RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events in patients undergoing RLT with (177)Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EJNMMI Res
Main Authors: Groener, Daniel, Nguyen, Cam Tu, Baumgarten, Justus, Bockisch, Benjamin, Davis, Karen, Happel, Christian, Mader, Nicolai, Nguyen Ngoc, Christina, Wichert, Jennifer, Banek, Severine, Mandel, Philipp, Chun, Felix K. H., Tselis, Nikolaos, Grünwald, Frank, Sabet, Amir
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8254689/
https://ncbi.nlm.nih.gov/pubmed/34216290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-021-00805-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados